Budd-Chiari syndrome classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 23: Line 23:
**Chronic: Associated with complications of cirrhosis.
**Chronic: Associated with complications of cirrhosis.
**Fulminant liver failure: Characterized by acute liver injury with elevated transaminases, jaundice, hepatic encephalopathy, and an elevated prothrombin time/international normalized ratio; hepatic encephalopathy develops within eight weeks after the development of jaundice.
**Fulminant liver failure: Characterized by acute liver injury with elevated transaminases, jaundice, hepatic encephalopathy, and an elevated prothrombin time/international normalized ratio; hepatic encephalopathy develops within eight weeks after the development of jaundice.
venous collaterals are not developed in patients with acute liver failure or acute liver disease whereas venous collaterals are seen in patients with subacute and chronic liver disease.
*Venous collaterals are not developed in patients with acute liver failure or acute liver disease whereas venous collaterals are seen in patients with subacute and chronic liver disease.
*Budd-Chiari syndrome may be classified according to anatomical location into [number] subtypes/groups: [group1], [group2], [group3], and [group4]
*Budd-Chiari syndrome may be classified according to anatomical location into [number] subtypes/groups: [group1], [group2], [group3], and [group4]


==References==
==References==

Revision as of 06:01, 2 November 2017

Budd-Chiari syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Budd-Chiari syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Budd-Chiari syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Budd-Chiari syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Budd-Chiari syndrome classification

CDC on Budd-Chiari syndrome classification

Budd-Chiari syndrome classification in the news

Blogs on Budd-Chiari syndrome classification

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Budd-Chiari syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Classification

  • Budd-Chiari syndrome may be classified into several subtypes based on:
    • Etiology
    • Disease duration and severity
    • Anatomical location and Extent of the outflow obstruction
  • An obstruction below 300µm in diameter is not considered as BCS by some authors.
  • Budd-Chiari syndrome may be classified according to etiology into two subtypes/groups
    • Primary:Hepatic venous outflow obstruction is a result of thrombosis.
    • Secondary:Hepatic venous outflow obstruction is a result of invasion or compression by a tumor.
  • Budd-Chiari syndrome may be classified according to disease duration and severity into four subtypes/groups:
    • Acute: Rapid development of clinical manifestations within weeks with intractable ascites and hepatic necrosis.
    • Subacute:Insidious onset symptoms develop over 3 months.Clinical manifestations of Ascites and hepatic necrosis may be minimal as portal and hepatic venous collaterals help in decompression of sinusoids.
    • Chronic: Associated with complications of cirrhosis.
    • Fulminant liver failure: Characterized by acute liver injury with elevated transaminases, jaundice, hepatic encephalopathy, and an elevated prothrombin time/international normalized ratio; hepatic encephalopathy develops within eight weeks after the development of jaundice.
  • Venous collaterals are not developed in patients with acute liver failure or acute liver disease whereas venous collaterals are seen in patients with subacute and chronic liver disease.
  • Budd-Chiari syndrome may be classified according to anatomical location into [number] subtypes/groups: [group1], [group2], [group3], and [group4]

References

Template:WS Template:WH